RECRUITING

Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib

Description

The goal of this observational study is to better understand real-world use of vimseltinib, treatment patterns, and health-related quality of life in participants treated with vimseltinib for TGCT. This study will collect data in an observational disease registry involving no intervention to the participants and will not influence standard medical care or impact treatment decisions for participants.

Conditions

Tenosynovial Giant Cell Tumor
Talk to us

Related Conditions:

Tenosynovial Giant Cell Tumor

Study Overview

On this page

Study Details

Study overview

The goal of this observational study is to better understand real-world use of vimseltinib, treatment patterns, and health-related quality of life in participants treated with vimseltinib for TGCT. This study will collect data in an observational disease registry involving no intervention to the participants and will not influence standard medical care or impact treatment decisions for participants.

Real-World Patient Experience of Vimseltinib for the Treatment of Tenosynovial Giant Cell Tumor

Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib

Condition
Tenosynovial Giant Cell Tumor
Intervention / Treatment

-

Contacts and Locations

Wilmington

Synexus Clinical Research, US INC, Wilmington, North Carolina, United States, 28401

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Diagnosis of TGCT according to medical records
  • 2. Prescribed vimseltinib per the approved label requirements. Participants are eligible if either (A) the decision to receive vimseltinib has been made but treatment has not yet been initiated or (B) the decision to receive vimseltinib has been made and participant has received first dose of prescribed vimseltinib less than 6 months prior to study enrollment
  • 3. Has provided informed consent and medical records release
  • 1. Participant has received any other systemic agent for the treatment of TGCT during the 6 months prior to starting treatment with vimseltinib
  • 2. Participant has received the first dose of prescribed vimseltinib in the current treatment course more than 6 months before study enrollment
  • 3. Participant is active in an interventional clinical trial of vimseltinib

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Deciphera Pharmaceuticals, LLC,

Clinical Team, STUDY_DIRECTOR, Deciphera Pharmaceuticals, LLC

Study Record Dates

2027-09